Pulmonary Drug Delivery Technologies - A Global Market PerspectiveBizAcumen, Inc.November 1, 2009 165 Pages - SKU: BZAC2521969 |
|
Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized
|
more...
|
$5,175.00
|
|
Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Peptides
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012 provides data on the Bronchopulmonary Dysplasia clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
|
Lung Injury Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Lung Injury Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Lung Injury Global Clinical Trials Review, H1, 2012 provides data on the Lung Injury clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
|
Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012 provides data on the Viral Respiratory Tract Infection clinical trial scenario. This
|
more...
|
$1,000.00
|
|
Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth
4/30/2012 | published by: GBI Research
Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth Summary GBI Research, the leading business intelligence provider, has released its latest research “Oral Drug Delivery Market
|
more...
|
$3,500.00
|
|
Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lung Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized
|
more...
|
$5,175.00
|
|
Obstructive Pulmonary Disease Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Obstructive Pulmonary Disease Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Obstructive Pulmonary Disease Global Clinical Trials Review, H1, 2012 provides data on the Obstructive Pulmonary Disease clinical trial scenario. This report provides elemental
|
more...
|
$1,000.00
|
|
Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
2/29/2012 | published by: GlobalData
Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, “Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report
|
more...
|
$3,995.00
|
Related Markets
Respiratory/Pulmonary Reports
- Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors
- Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
- Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012
